



AN ISRAELI SME DEVELOPING AI-BASED INTERPRETATION ENGINE FOR GENOMIC DATA

Looking to join a consortium settings up a proposal for submission under IMI call topic 4 - [Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence](#)

ABOUT GENOOX

[Genoox](#) is a Healthcare Technology company developing an AI-based interpretation engine for genomic data. Our engine is built and trained on top of the Genoox Community Data - a unique crowdsourced dataset which differentiates our solution making it accurate and based on real-world evidence. To date, the interpretation engine supports multiple applications including rare diseases, oncology, hereditary cancer and carrier screening.

We are looking to join a consortium, where we would take the lead or active role in AI and novel algorithm development and data analysis.

The consortia that may benefit from our contribution, experience and expertise

An established or forming consortium that has partners with access to patients and clinical data, high familiarity with cancer and solid tumor treatment and decision support processes today in the clinical practice and access to cancer related resources.

Our specific potential contribution

Our role in a potential consortium could be leading and achieving “Work package 3 – Guideline-based decision support tool”. The Genoox AI-based interpretation engine already supports decision making for cancer patients (at the case level), based on genomic data and clinical background. NCCN guidelines are incorporated into the engine. In addition to prioritization of genetic markers, the platform provides the entire evidence including relevant clinical trials and drugs. As part of this process, the engine prioritizes variants according to the AMP, ASCO, CAP Guidelines in a tiered classification system. Moreover, AI and NLP methods are used to extract evidence from unstructured data sources including scientific publications.



The Genoox platform is being used by hundreds of organizations around the world for genetic interpretation based on panels, exomes and genomes for various use cases, including cancer and rare diseases. Our team is composed from highly skilled bioinformaticians, data scientists, software engineers as well as geneticists and clinicians. Our community edition is freely available at <https://franklin.genoox.com/> and can give a sense of what we do and excel at. To date we won multiple grants from the Israeli Innovation Authority and [BIRD foundation](#) and are experienced in working and leading similar projects. We were [recognized](#) as one of top 5 startups disrupting healthcare with AI by Business Insider and Customer Value Leadership award for Genetic Analysis Market by Frost & Sullivan.

Groups that are setting up a proposal are invited to contact:

Moshe Einhorn | CTO and co-founder
moshe@genoox.com